Does delaying surgery following induction chemotherapy compromise survival in patients with mesothelioma?

Abstract

Objective: The ideal time interval between induction chemotherapy and surgery and the impact on cancer mortality in patients with mesothelioma remains unclear.

Methods: We queried the National Cancer Database (2004-2017) for patients with favorable prognostic factors considered for surgery. Immediate surgery was performed within 3 months following the start of induction chemotherapy, while delayed surgery was defined as surgery performed later than 3 months. We compared both groups to those who did not have an operation despite being surgical candidates, as well as to those who were treated with surgery only. Overall mortality was assessed using Cox proportional hazard models adjusting for covariates.

Results: A total of 4,294 patients were included, with the majority of patients undergoing induction chemotherapy followed by no surgery (3,370, 78%). The proportion of patients undergoing both immediate and delayed surgery increased over the last decade, but delayed surgery continued to be more common. There were no significant differences in baseline characteristics between the immediate and delayed surgery groups. Higher comorbidity scores were significantly associated with an increased risk of death on multivariable analysis, but the timing of surgery was not. This held true with a sensitivity analysis using 6 months as the definition of delayed surgery.

Conclusions: This study shows that delaying surgery following induction chemotherapy does not compromise overall survival in patients with mesothelioma.

Keywords

Malignant pleural mesothelioma / mesothelioma surgery / mesothelioma treatment

References

[1] Baas P,Kerr KM,Haas RL.ESMO Guidelines CommitteeMalignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol2015;26 Suppl 5:v31-9

[2] Waller DA.Randomized controlled trials in malignant pleural mesothelioma surgery-mistakes made and lessons learned.Ann Transl Med2017;5:240 PMCID:PMC5497113

[3] Kindler HL,Armato SG 3rd.Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline.J Clin Oncol2018;36:1343-73 PMCID:PMC8058628

[4] NCCN Clinical Practice Guidelines in Oncology. Malignant Pleural Mesothelioma; 2019. Available from: https://www.nccn.org/ [Last accessed on 30 August 2023]

[5] Nakas A.Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.Eur J Cardiothorac Surg2014;46:380-5; discussion 385

[6] Meyerhoff RR,Speicher PJ.Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.J Surg Res2015;196:23-32 PMCID:PMC4430361

[7] Rice D.Surgical therapy of mesothelioma.Recent Results Cancer Res2011;189:97-125

[8] Kindler HL.Surgery for mesothelioma? The debate continues.Lancet Oncol2011;12:713-4

[9] Cao C,Park J,Pataky KA.A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.Lung Cancer2014;83:240-5

[10] Takuwa T.Current surgical strategies for malignant pleural mesothelioma.Surg Today2016;46:887-94

[11] Hasegawa S.Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma.Gen Thorac Cardiovasc Surg2014;62:516-21

[12] Tsao AS,Roth JA.Malignant pleural mesothelioma.J Clin Oncol2009;27:2081-90 PMCID:PMC4881753

[13] Bovolato P,Billè A.Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients.J Thorac Oncol2014;9:390-6

[14] Treasure T,Waller D.Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.Lancet Oncol2011;12:763-72 PMCID:PMC3148430

[15] Burt BM,Mollberg NM.Malignant pleural mesothelioma and the society of thoracic surgeons database: an analysis of surgical morbidity and mortality.J Thorac Cardiovasc Surg2014;148:30-5

[16] Bilimoria KY,Winchester DP.The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.Ann Surg Oncol2008;15:683-90 PMCID:PMC2234447

[17] American College of Surgeons. National Cancer Data Base Participant Use Data File (PUF) Data Dictionary. 2004-2014. Available from: https://www.facs.org/media/brilfbgu/puf-2020-data-dictionary.pdf [Last accessed on 15 Sep 2023]

[18] Saddoughi SA,Blackmon SH.National trends in the epidemiology of malignant pleural mesothelioma: a national cancer data base study.Ann Thorac Surg2018;105:432-7

[19] Rosskamp M,Nackaerts K.Real-life treatment practice for malignant pleural mesothelioma in Belgium.Lung Cancer2018;125:258-64

[20] Espinoza-mercado F,Borgella JD,Soukiasian HJ.Neoadjuvant versus adjuvant chemotherapy for resectable malignant pleural mesothelioma: an analysis of the National Cancer Database.J Clin Oncol2018;36:e20556

[21] Lim E,Patel A,Edmonds L.Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials.J Thorac Oncol2009;4:1380-8

[22] Felip E,Maestre JA.Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.J Clin Oncol2010;28:3138-45

[23] Belani CP.Adjuvant and neoadjuvant therapy in non-small cell lung cancer.Semin Oncol2005;32:S9-15

[24] Beckert AK,Thompson K.Screening for frailty in thoracic surgical patients.Ann Thorac Surg2017;103:956-61 PMCID:PMC5944327

[25] Tsiouris A,Velanovich V,Borgi J.A modified frailty index to assess morbidity and mortality after lobectomy.J Surg Res2013;183:40-6

[26] Wahl TS,Hawn MT.Association of the modified frailty index with 30-day surgical readmission.JAMA Surg2017;152:749-57 PMCID:PMC5710500

[27] Kojima G,Walters K.Frailty index as a predictor of mortality: a systematic review and meta-analysis.Age Ageing2018;47:193-200

[28] Pleurectomy/Decortication (P/D) preceded or followed by chemotherapy in patients with early stage MPM. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT02436733 [Last accessed on 30 August 2023].

[29] Baas P,Nowak AK.First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.Lancet2021;397:375-86

[30] Lim E,Edwards J.Mesothelioma and radical surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma.BMJ Open2020;10:e038892 PMCID:PMC7467531

[31] Warnock C,Taylor B.Patient experiences of participation in a radical thoracic surgical trial: findings from the mesothelioma and radical surgery trial 2 (MARS 2).Trials2019;20:598 PMCID:PMC6798336